IMMUNEX CORP /DE/
SC 13G/A, 1999-02-11
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: FIDELITY ADVISOR SERIES IV, 497, 1999-02-11
Next: CLAYTON HOMES INC, 10-Q, 1999-02-11







                        SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C. 20549

                                   SCHEDULE 13 G
                     Under the Securities Exchange Act of 1934




Amendment No.                           2*


Name of Issuer:                         IMMUNEX CORP


Title of Class of Securities:           COMMON


CUSIP Number:                           45252810





*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover age.

The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section
18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act
(however, see the Notes).




                                    Page 1 of 4


<PAGE>


CUSIP NO.     45252810

1.       Name of Reporting Person, S.S. or I.R.S. Identification No.
         of above person:

         First Manhattan Co.             13-1957714


2.       Check the appropriate box if a member of a group:
                                         (a) [    ]
                                         (b) [ X ]

3.       SEC Use Only


4.       Citizenship or Place of Organization:
                 
                        New York

         NUMBER OF SHARES BENEFICIALLY OWNED
         BY EACH REPORTING PERSON WITH:

5.       Sole Voting Power:                       30,500


6.       Shared Voting Power:                     1,507,959


7.       Sole Dispositive Power:                  30,500


8.       Shared Dispositive Power:                1,550,459


9.       Aggregate Amount Beneficially Owned by
             Each Reporting Person:               1,580,959**


10.      Check Box If The Aggregate Amount in Row (9)
         excludes Certain Shares        [    ]

11.      Percent of Class Represented by Amount in Row 9:   3.90%

12.      Type of Reporting Person:

                      BD, IA, PN

- ----------------------
** Includes 82,750 shares owned by family members of General  Partners of First
Manhattan  Co.  which are  being  reported  for  informational  purposes.  First
Manhattan  Co.  disclaims  dispositive  power as to  69,650 of such  shares  and
beneficial ownership as to 13,100 of such shares.

                                    Page 2 of 4

<PAGE>

Item 1(a)    Name of Issuer:                      IMMUNEX CORP

Item 1(b)    Address of Issuer's
             Principal Executive Offices:         51 UNIVERSITY STREET
                                                  SEATTLE, WA   98101

Item 2(a)    Name of Person Filing:               First Manhattan Co.

Item 2(b)    Address Principal Business Office:
                                                  437 Madison Avenue
                                                  New York, NY 10022

Item 2(c)    Citizenship:                         U.S.A.

Item 2(d)    Title of Class of Securities:        COMMON

Item 2(e)    CUSIP Number:                        45252810

Item 3       Check whether the person filing is a:

Item 3(a)     [X]     Broker or Dealer registered under Section 15 of the Act.

Item 3(b) - (d)       Not applicable.

Item 3(e)    [X]      Investment Advisor registered under Section 203
                      of  the Investment Advisors Act of 1940.

Item 3(f) - (h)       Not applicable.

Item 4(a)    Amount Beneficially Owned:                      1,580,959**

Item 4(b)    Percent of Class:                               3.90%

Item 4(c)    Number of shares as to which such person has:

(i) sole power to vote or to direct the vote                 30,500

(ii) shared power to vote or to direct the vote              1,507,959

(iii) sole power to dispose or to direct the
             disposition of                                  30,500

(iv) shared power to dispose or to direct the
             disposition of                                  1,550,459

Item 5   Ownership of Five Percent or Less of Class:         [  X ]


Item 6   Ownership of More than Five Percent
             on Behalf of Another Person:           Not applicable.


** Includes  82,750 shares owned by family members of General  Partners of First
Manhattan  Co.  which are  being  reported  for  informational  purposes.  First
Manhattan  Co.  disclaims  dispositive  power as to  69,650 of such  shares  and
beneficial ownership as to 13,100 of such shares.

                                    Page 3 of 4


<PAGE>

Item 7      Identification and Classification of the Subsidiary
         Which Acquired the Security Being Reported on
                By the Parent Holding Company          Not applicable.


Item 8   Identification and Classification of Members
         Of the Group                                  Not applicable.


Item 9   Notice of Dissolution of Group                Not applicable.


Item 10  Certification.


By signing below I certify  that,  to the best of my knowledge  and belief,  the
securities  referred to above were  acquired in the ordinary  course of business
and were not  acquired for the purpose of and do not have the effect of changing
or  influencing  the  control  of the  issuer  of such  securities  and were not
acquired in connection with or as a participant in any  transaction  having such
purpose or effect.

Signature:

After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.



February 11, 1999
- ----------------------------------------------
Date



- -----------------------------------------------
Signature


Neal K. Stearns, General Partner
- ------------------------------------------------
Name/Title



                                    Page 4 of 4




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission